Association between venous thromboembolism and plasma levels of both soluble fibrin and plasminogen-activator inhibitor 1 in 170 patients undergoing total hip arthroplasty

Yohei Yukizawa¹, Yutaka Inaba², Shin-ichiro Watanabe³, Satoshi Yajima³, Naomi Kobayashi², Takashi Ishida¹, Naoyuki Iwamoto¹, Hyonmin Choe¹, and Tomoyuki Saito¹,²

¹Musculoskeletal Science, Yokohama City University Graduate School of Medicine; ²Department of Orthopaedic Surgery, Yokohama City University School of Medicine; ³Department of Clinical Laboratories, Yokohama City University Hospital, Yokohama, Japan

Correspondence YI: yute@yhc.att.ne.jp
Submitted 11-03-25. Accepted 11-09-05

Background and purpose   Markers of coagulation and fibrinolysis, such as soluble fibrin (SF), D-dimer, and plasminogen-activator inhibitor 1 (PAI-1), have been developed in order to determine thrombotic tendency. We investigated whether these markers could be used to diagnose venous thromboembolism (VTE) in the early phase after primary total hip arthroplasty (THA).

Methods   This prospective study involved 2 groups: an intermittent pneumatic compression (IPC) group (67 patients who underwent IPC only as prophylaxis for VTE) and a fondaparinux (FPX) group (103 patients who received IPC and FPX postoperatively). Plasma levels of SF and PAI-1 were measured on postoperative day 1. To diagnose postoperative VTE, multi-detector row computed tomography (MDCT) and duplex ultrasonography (US) were performed on postoperative day 7.

Results   VTE was detected postoperatively in 17 cases in the IPC group (25%) and in 8 cases in the FPX group (6%). In the IPC group, plasma levels of SF and PAI-1 were higher in patients with VTE (p < 0.01) than in those without VTE. On the other hand, in the FPX group there were no differences in the levels of SF or PAI-1 measured before administration of FPX on postoperative day 1. The diagnostic criterion of an increase in SF or PAI-1 measured before administration of FPX on postoperative day 1 provided a sensitivity of 100% and a specificity of 67% in the IPC group. In addition, when this criterion was applied to FPX patients, 7 of the 8 patients with VTE met the criterion, and there was a negative agreement rate of 48/49.

Interpretation   Screening using the cutoff levels of SF and PAI-1 may be useful and shows high sensitivity in predicting postoperative VTE in the early phase after THA.
of specific and sensitive tests that can detect thrombosis. At the same time, many different markers have been found to show increased expression in clinical disorders in which there is an imbalance between coagulation and fibrinolysis. We examined acute postoperative changes in (1) soluble fibrin (SF), a complex of fibrin monomer and fibrinogen derivatives; (2) thrombin-antithrombin complex (TAT), a marker of thrombin generation; (3) D-dimer, a proteolytic fragment resulting from degradation of a fibrin clot; and (4) plasminogen-activator inhibitor 1 (PAI-1), which is the main regulator of the fibrinolysis system. In addition, we evaluated the usefulness of assaying these markers as predictors of early VTE following THA.

Patients and methods

170 patients with a mean age of 63 (38–85) years who were scheduled for THA between 2007 and 2010 were included. Patients were excluded if they had any of the following conditions: (1) a prior THA requiring revision; (2) a previous history of VTE; (3) a pre-existing malignant tumor; or (4) renal failure (estimated glomerular filtration rate < 50 mL·min⁻¹·1.73 m⁻²). Before surgery, all patients were provided with a detailed explanation of the risks and alternatives to participation in the study, and all provided written informed consent. The study was approved by the Institutional Review Board of Yokohama City University (approval no., 01-10-2007-058).

Prophylaxis for VTE

There were 2 patient groups: the IPC group (67 patients who underwent primary THA between 2007 and 2008) and the fondaparinux (FPX) group (103 patients who underwent THA between 2008 and 2010). At our institution, FPX has been used routinely since September 2008. IPC was performed on all patients in both groups during surgery (under anesthesia), and the patients were given unfractionated heparin (UFH) intravenously in a single dose of 20 IU/kg of body weight (Sharrock et al. 1999). IPC was maintained postoperatively. Patients usually started walking 1–2 days after surgery. The patients in the FPX group were also given 2.5 mg of FPX subcutaneously every day for 14 days, starting on postoperative day 1.

Perioperative management

All patients were operated under general anesthesia. THA using a computed tomography-based navigation system was performed through a minimally-invasive anterolateral approach with the patient in the lateral decubitus position. During surgery, all patients received up to 1,500 mL of Ringer’s solution or hydroxyethyl starch. Fluid management after surgery until the next morning was routinely done with 1,000 mL of Ringer’s solution and 500 mL of maintenance fluid.

Postoperative mobilization followed a protocol supervised by experienced orthopedic physiotherapists. The patients were allowed discharge on postoperative day 14, the day this mobilization protocol was completed.

Diagnostic methods for VTE

Duplex ultrasonography (US) was performed on all patients 28 days before surgery in order to detect any evidence of previous DVT of the lower limb. Absent or incomplete compressibility of the vein was the diagnostic criterion. For the determination of postoperative VTE, an angiography of the pulmonary artery and deep veins on the pelvis and the lower limbs was performed on all patients on postoperative day 7, by 64-slice multidetector row computed tomography (MDCT) using a nonionic contrast agent. The diagnostic criterion for VTE was the presence of a defect of intraluminal filling because of thrombosis in the pulmonary artery or deep vein. When the presence of VTE was suspected by MDCT, a duplex US was also employed in order to confirm the presence of DVT.

Following detection of the postoperative VTE, patients with VTE were administered UFH intravenously in order to maintain the activated partial thromboplastin time at 1.5–2.5 times that of the control value. Warfarin was administered at the same time, and the international normalized ratio was maintained at 2.0–2.5.

Blood samples

Blood samples were obtained from peripheral veins under short fasting conditions early in the morning, on the preoperative day and on postoperative days 1, 3, 7, and 14. Plasma SF levels were measured using a latex photometric immunoassay (IATRO SF II; Mitsubishi Chemical Medience Corporation, Tokyo, Japan) with IF-43 monoclonal antibody raised against a urea-solubilized fibrin monomer. The normal upper limit for SF was < 7 µg/mL. PAI-1 was measured using a latex photometric immunoassay (LPIA-tPAI Test; Mitsubishi Chemical Medience Corporation) using a reference range of 10–50 ng/mL. Furthermore, preoperative levels of lipids such as triglycerides and total cholesterol were measured, and their association with PAI-1 was determined. Plasma D-dimer levels were also assayed with a latex photometric immunoassay (LPIA-ACE D-dimer; Mitsubishi Chemical Medience Corporation). The normal limit was < 0.7 µg/mL. TAT was measured by enzyme-linked immunosorbent assay (ELISA) with a reference range of 0.1–5.0 ng/mL (Enzygnost TATmicro; Siemens Healthcare Diagnostics Inc., Tokyo, Japan).

Statistics

Statistical analyses were performed using SPSS II software. According to a Kolmogorov-Smirnov analysis, the coagulation and fibrinolysis variables showed a skewed distribution. Thus, these variables are presented as medians. The medians and interquartile ranges are plotted in the figures as a box-and-whisker plot. In the figures, the vertical bars (whiskers) represent the 5th and 95th percentiles and the horizontal bars in the boxes represent the medians. In addition, differences in
the variables between patients with VTE and those without were examined statistically using Student’s t-test or a two-tailed Mann-Whitney U-test. Furthermore, the chi-square test and Fisher’s exact probabilities were used for the comparison between the observed and expected frequencies. The usefulness of the markers for the diagnosis of VTE was assessed by a receiver operating characteristic curve analysis. Values of p < 0.05 were considered statistically significant.

Results

In the IPC group, postoperative VTE was detected in 17 of the 67 patients (25%), and the incidences of pulmonary embolism (PE) only, deep vein thrombosis (DVT) only, and both PE and DVT were 3, 12, and 2, respectively. In the FPX group, VTE was detected in 8 of the 103 patients (7%), and the incidences of PE only, DVT only, and both PE and DVT were 3, 5, and 0, respectively. The difference in the frequency of occurrence of VTE between the IPC and FPX groups was statistically significant (p < 0.01). All DVT occurred in the calf vein, and there were no cases of symptomatic DVT or PE. The distributions of age, sex, body mass index (BMI), duration of surgery, blood loss, and previous illness were similar in patients with and without VTE, and between the IPC and FPX groups (Table).

In the IPC group, plasma SF levels on postoperative day 1 in patients with VTE were higher than those in patients without VTE (p < 0.01) (Figure 1), and the median values were 38 µg/mL and 10 µg/mL, respectively. Plasma SF levels rapidly decreased to reference range by postoperative day 3. On the other hand, in the FPX group SF levels were similar in patients with and without VTE (Figure 2).

In the IPC group, plasma PAI-1 levels on postoperative day 1 in patients with VTE were higher than those in patients without VTE (p < 0.01) (Figure 1). The median PAI-1 values on postoperative day 1 were 93 ng/mL for patients with VTE and 40 ng/mL for patients without VTE. In addition, in both the IPC and FPX groups plasma D-dimer levels showed bimodal peaks that were evident on postoperative days 1 and 7. In the IPC group, significant differences in the plasma D-dimer levels were not seen on postoperative day 1, but they were seen on postoperative day 7 (p < 0.01). The median D-dimer values on day 7 were 21 µg/mL for patients with VTE and 10 µg/mL for patients without VTE (Figures 1 and 2).

IPC patients with VTE also showed higher levels of TAT on postoperative day 1 (p < 0.05); the median values were 24 µg/mL for patients with VTE and 14 µg/mL for patients without VTE. On the other hand, statistically significant differences in TAT levels were not found in patients of the FPX group.

To evaluate the usefulness of the markers SF, PAI-1, and TAT that were detected in the IPC group on postoperative day 1, their cutoff levels with sensitivities and specificities were determined by receiver operating characteristic (ROC) analysis (Figure 3). The cutoff level of SF was determined to be 19.8 µg/mL, with a sensitivity of 88% and a specificity of 62%. The cutoff level of PAI-1 was 53.5 ng/mL, with a sensitivity of 78% and a specificity of 72%, and that of TAT was found to be 18.1 ng/mL with a sensitivity of 85% and a specificity of 66%. Next, using a multivariate logistic regression analysis, we found that SF and PAI-1 levels on postoperative day 1 had statistically the strongest association with thrombotic tendency. Furthermore, comparison of the area under the ROC curves showed that the measurements of SF and PAI-1 on postoperative day 1 had the best performance with respect
Figure 1. Changes in coagulation markers in patients who underwent intermittent pneumatic compression only. Plasma levels of soluble fibrin (SF), plasminogen activator inhibitor type 1 (PAI-1), D-dimer, and thrombin-antithrombin complex (TAT) in patients who underwent intermittent pneumatic compression alone were measured preoperatively and on postoperative days 1 (PO1D), 3 (PO3D), 7 (PO7D), and 14 (PO14D). The boxes represent the interquartile ranges. The perpendicular lines (whiskers) represent the fifth and ninety-fifth percentiles and the horizontal bars in the boxes indicate the median values. On the day after surgery, the plasma levels of SF, PAI-1, and TAT were found to be increased in the venous thromboembolism (VTE) group compared to the non-VTE group. The changes in the D-dimer levels showed bimodal peaks on postoperative days 1 and 7 in both groups. Statistically significant differences were observed in the D-dimer levels measured on postoperative day 7. a p < 0.05 and b p < 0.01.

Figure 2. Changes in coagulation markers in patients who received subcutaneous injections of fondaparinux sodium. Plasma levels of soluble fibrin (SF), plasminogen activator inhibitor type 1 (PAI-1), D-dimer, and thrombin-antithrombin complex (TAT) in patients who received subcutaneous injections of fondaparinux sodium were measured preoperatively and on postoperative days 1 (PO1D), 3 (PO3D), 7 (PO7D), and 14 (PO14D). The boxes represent the interquartile ranges. The perpendicular lines represent the fifth and ninety-fifth percentiles and the horizontal bars in the boxes indicate the median values. The levels of SF, PAI-1, D-dimer, and TAT were similar in the patients in the fondaparinux group who had or did not have VTE.
Figure 3. Receiver operating characteristic (ROC) curve analysis of the accuracy of the quantitative soluble fibrin (SF), plasminogen activator inhibitor type 1 (PAI-1), and thrombin-antithrombin complex (TAT) levels on postoperative day 1 and D-dimer levels on day 7. The area under the ROC curve (AUC) is given in each diagram with the 95% confidence interval in parentheses.

Figure 4. Discrimination of postoperative venous thromboembolism (VTE) using levels of soluble fibrin (SF) and plasminogen activator inhibitor type 1 (PAI-1). Increases in either SF or PAI-1 on postoperative day 1 above their cut-off levels provided 100% sensitivity and 67% specificity in predicting VTE when patients were not given fondaparinux sodium postoperatively (left panel). In addition, when this criterion was applied to patients who received subcutaneous injections of fondaparinux following surgery, 7 of the 8 patients with VTE met the criterion and there was a negative agreement rate of 98.0% (48/49).

Discussion

VTE is a common complication after total hip or knee arthroplasty, but most VTE is generally asymptomatic. Due to the lack of symptoms, the condition goes mostly unnoticed and the patient is therefore left untreated. However, approximately 10–20% of crural thrombi, most of which are asymptomatic DVT, move to the proximal veins (Labropoulos et al. 2002). Proximal propagation of a thrombus can lead to free-floating...
status, resulting in critical complications after being released as a massive embolus (Balridge et al. 1990). According to the PREVENT study (Ridker et al. 2003), the recurrence rate of VTE is approximately 7%, and long-term, low-intensity warfarin therapy reduces this risk by more than half. Thus, we suggest that all cases of VTE—including asymptomatic VTE—should be detected and treated with anticoagulants, and that an early and simple modality for screening of VTE should be established.

Highly invasive surgery has been shown to commonly result in a hypercoagulable state and increasing plasma levels of SF and TAT during the initial postoperative stage (Brueckner et al. 2003, Sudo et al. 2009). This is consistent with our present findings that plasma SF and TAT levels were elevated on postoperative day 1. Also, considering the substantial elevation of these markers in patients who developed VTE in the IPC group, we suggest that the onset of VTE is associated with a hypercoagulable state in the early phase after THA.

A high level of SF in clinical plasma samples has been recognized to be an indicator of ongoing intravascular coagulation processes (Hamano et al. 2005). SF expresses an acute intravascular fibrin formation as well because SF is one of circulating materials growing fibrin clots. Regarding the usefulness of SF for possible diagnosis of VTE, it was previously suggested that SF levels on the day after total hip or knee arthroplasty may be valuable for prediction of postoperative VTE (Sudo et al. 2009, Niimi et al. 2010).

Similarly to SF, TAT is considered to be associated with VTE following THA (Sudo et al. 2009). Formation of TAT is, however, only an indirect measure of an activated coagulation system (Brueckner et al. 2003), and its measurement is often influenced by the peripheral blood sampling techniques used under venous occlusion. Sensitivity and specificity of TAT measurement on the day after THA have been reported to be 73% and 27%, respectively (Cofrancesco et al. 1998). Thus, TAT has been found to be inferior to other markers as a predictor of VTE (Brueckner et al. 2003, Hamano et al. 2005).

PAI-1 is the principal inhibitor and critical regulator of plasminogen activator. Several clinical studies have found that plasma PAI-1 levels may be affected by lipid levels or vascular endothelial cell injury, and these factors may therefore increase the risk of thrombosis or embolism (Hamsten et al. 1987, Juhan-Vague et al. 1987). Furthermore, PAI-1 is produced at the site of inflammation following tissue injury. It has been reported that plasma PAI-1 levels are associated with surgical invasion, and that the increased levels of the fibrinolytic inhibitor that result from this may therefore be a major contributor to fibrinolytic shutdown (Kassis et al. 1992). In the present study, plasma PAI-1 levels were substantially elevated in IPC patients with VTE, despite the absence of any significant differences in other thrombotic risk factors such as lipid levels, BMI, or pre-existing diseases. Thus, we believe that changes in the fibrinolytic system may also be associated with the development of VTE.

Plasma D-dimer levels increase after the cleavage of formed thrombi by activated plasmin, and they have been suggested to be a useful marker for the diagnosis of VTE. The sensitivity and specificity for proximal DVT were 79% and 36%, respectively. In the present study, D-dimer measurements on postoperative day 7 were different in patients with and without VTE in the IPC group. However, at this stage, VTE is already evident, and we therefore suggest that D-dimer is not useful as an early predictor of this disorder.

An imbalance between coagulation and fibrinolysis contributes to excessive fibrin deposition in the vascular wall because both systems are composed of a complex cascade of molecules and closely influence each other (Aso 2007). Our results indicate that this imbalance can be detected with a combined assay involving SF as a coagulation marker and PAI-1 as a fibrinolytic marker. As shown in Figure 4, some of the patients with VTE had high levels of SF but low PAI-1 levels, whereas some had low SF levels and high PAI-1 levels. These data suggest that the onset of VTE after THA may be due to a hypercoagulable state, a highly regulated fibrinolytic state, or both.

We think that the combined measurement of SF and PAI-1 on postoperative day 1 is a useful screening method for patients who are at high risk of developing postoperative VTE. Our findings suggest that plasma levels of SF and PAI-1 on postoperative day 1 have the potential to provide an alternative chemoprophylaxis regimen for VTE after THA. However, the high sensitivity of this screening for prediction of VTE on day 7 was observed in patients receiving perioperative heparin and short-term IPC. It is necessary to investigate this further using different thromboprophylaxis methods and various imaging modalities. In addition, investigation of late VTE, which occurs 2–3 months after surgery, should be performed to confirm whether chemoprophylaxis is necessary for low-risk patients.

The levels of SF, PAI-1, TAT, and D-dimer in patients in the FPX group were similar between patients with and without VTE. This is because the use of FPX regulated the hypercoagulable state and the formation of thrombi, even in patients whose levels of coagulation markers were high in the early phase of surgery. Also, the reason why there were no differences in the levels of D-dimer between patients with and without VTE may be that FPX functioned as a treatment agent for already-developed VTE.

In both the IPC and FPX groups, VTE may have developed in some cases before the first measurements. Thus, delayed screening for VTE—i.e. on the day after the surgery—was not helpful, and screening should ideally be performed during or immediately after the surgery. Only 1 Japanese study has examined SF levels in the perioperative period following THA, and was unable to demonstrate the usefulness of these markers during or immediately after surgery because of a variety of factors. Although our measurements were delayed, our method is one of the fastest for screening of patients who are at high risk of developing VTE.
A 64-slice MDCT was employed as the imaging modality for the detection of postoperative VTE in this study, because with this technique one can simultaneously perform both pulmonary angiography and venography of the lower extremities. In addition, it is a less invasive technique than conventional ascending venography, requires considerably less time (approximately 5–8 min), and is technically simple (Lim et al. 2004). However, MDCT has several disadvantages, such as exposure of the patient to radiation, beam-hardening artifacts around the arthroplastic joint materials, and contrast-induced nephropathy. Concerning the accuracy of DVT detection since the advent of MDCT, several studies have shown that the diagnostic ability of indirect CT venography is comparable to US (Duwe et al. 2000, Loud et al. 2001, Lim et al. 2004), and both the sensitivity and the specificity in these studies ranged from 89–100%. US has recently become a widely accepted primary modality in the diagnosis of DVT because of its advantages, including high accuracy, painlessness, noninvasiveness, and reduced cost. Furthermore, US does not require radiation or contrast materials and there are no side effects. Thus, we employed duplex US for the preoperative screening of DVT and for postoperative confirmation of DVT suspected by MDCT.

In addition to imaging modalities, other factors may have affected the incidence of postoperative VTE, such as the method of anesthesia, duration of surgery, perioperative injection of heparin, immobilization, and duration of hospital stay (Husted et al. 2010, Brueckner et al. 2003). To minimize the influence of these factors on the occurrence of VTE, mobilization and rehabilitation directed by a physiotherapist were initiated within 24 hours of surgery. All patients underwent physiotherapy, and mobilization was frequently encouraged in free time during the hospital stay. Because of the limitation that the FPX injection can only be administered by nurses or doctors during the hospital stay and cannot be self-administered by patients at home, in Japan the duration of the hospital stay is longer than in other countries. The postoperative hypercoagulable state may change if epidural anesthesia is used (Brueckner et al. 2003) or if the duration of surgery is shortened. In the present study, a computed tomography-based navigation system was used to insert the joint implant accurately in all the patients. This system generally takes time to set and register. Furthermore, MIS techniques were used for all cases. It is possible that prolonged surgery may have resulted in the hypercoagulable state. Perioperative administration of heparin may also affect the incidence of postoperative VTE or the postoperative coagulation state, although the dose of heparin was considerably low.

In conclusion, patients undergoing primary THA are at a high risk of developing VTE, which is possibly induced by a hypercoagulable or regulated fibrinolytic state during the early postoperative phase. Plasma levels of SF and PAI-1 on day 1 after THA may be of value in providing an indication of the balance between coagulation and fibrinolysis, and in predicting VTE following THA. When high levels of SF or PAI-1 are observed on the day after surgery, there is a higher risk of postoperative VTE.

YY: design of the study, data collection, literature search, and manuscript preparation. YI: design of the study, surgery, manuscript preparation, and supervision. SW and SY: collection and evaluation of data. NK: design of the study and surgery. IT, NI, HC: design of the study and patient follow-up. TS: design of the study, manuscript preparation, and supervision.

We thank the following people for their contributions: Chie Aoki, Hiroshi Fujimaki, Hiroyuki Ike, Taro Tezuka, Yasuhide Hirata, Takako Momose, and Yushi Miyamae—all the orthopedic surgeons who participated at Yokohama City University.

No competing interests declared.

Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007; 12: 2957-66.
Baldrige E D, Martin M A, Welling R E. Clinical significance of free-floating venous thrombi. J Vasc Surg 1990; 11 (1): 62-7; discussion 8-9.
Brueckner S, Reinke U, Roth-Isigkeit A, Eleftheriadis S, Schmucker P, Siemens H J. Comparison of general and spinal anesthesia and their influence on hemostatic markers in patients undergoing total hip arthroplasty. J Clin Anesth 2003; 15 (6): 433-40.
Callaghan J J, Dorr L D, Engh G A, Hanssen A D, Healy W L, Lachiewicz P F, Lenner J H, Lofte P A, Ranawat C S, Ritter M A, Salvati E A, Sculco T P, Thornhill T S. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians—are they appropriate for orthopaedic surgery? J Arthroplasty 2005; 20 (3): 273-4.
Cofrancesco E, Cortellaro M, Corradi A, Ravasi F, Bertocci F. Clinical utility of prothrombin fragment 1+2, thrombin anti-thrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement. Thromb Haemost 1998; 79 (3): 509-10.
Dorr L D, Gendelman V, Maheshwari A V, Boutary M, Wan Z, Long W T. Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg (Am) 2007; 89 (12): 2648-57.
Duwe K M, Shiau M, Budorick N E, Austin J H, Berkmen Y M. Evaluation of the lower extremity veins in patients with suspected pulmonary embolism: a retrospective comparison of helical CT venography and sonography. 2000 ARRS Executive Council Award I. American Roentgen Ray Society. AJR Am J Roentgenol 2000; 175 (6): 1525-31.
Fuji T, Fujita S, Ochi T. Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients. Int Orthop 2008; 32 (4): 443-51.
Fujita S, Hirota S, Oda T, Kato Y, Tsukamoto Y, Fuji T. Deep venous thrombosis after total hip or total knee arthroplasty in patients in Japan. Clin Orthop 2000; (375): 168-74.
Geerts W H, Bergqvist D, Pineo G F, Heit J A, Samama C M, Lassen M R, Colwell C W. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (6 Suppl) 2008; 133: 381S-453S.
Hamano A, Umeda M, Ueno Y, Tanaka S, Mimuro J, Sakata Y. Latex immunoturbidimetric assay for soluble fibrin complex. Clin Chem 2005; 51 (1): 183-8.
Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2 (8549): 3-9.
Husted H, Otte K S, Kristensen B B, Ornes T, Wong C, Kehlet H. Low risk of thromboembolic complications after fast-track hip and knee arthroplasty. Acta Orthop 2010; 81 (5): 599-605.

Juhun-Vague I, Valadier J, Alessi M C, Aillaud M F, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57 (1): 67-72.

Kassis J, Hirsh J, Podor T J. Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis. Blood 1992; 80 (7): 1758-64.

Labropoulos N, Kang S S, Mansour M A, Giannoukas A D, Moutzouros V, Baker W H. Early thrombus remoulding of isolated calf deep vein thrombosis. Eur J Vasc Endovasc Surg 2002; 23 (4): 344-8.

Lim K E, Hsu W C, Hsu Y Y, Chu P H, Ng C J. Deep venous thrombosis: comparison of indirect multidetector CT venography and sonography of lower extremities in 26 patients. Clin Imaging 2004; 28 (6): 439-44.

Loud P A, Katz D S, Bruce D A, Klippenstein D L, Grossman Z D. Deep venous thrombosis with suspected pulmonary embolism: detection with combined CT venography and pulmonary angiography. Radiology 2001; 219 (2): 498-502.

Niimi R, Hasegawa M, Sudo A, Shi D, Yamada T, Uchida A. Evaluation of soluble fibrin and D-dimer in the diagnosis of postoperative deep vein thrombosis. Biomarkers 2010; 15 (2): 149-57.

Ridker P M, Goldhaber S Z, Danielson E, Rosenberg Y, Eby C S, Deitcher S R, Cushman M, Moll S, Kessler C M, Elliott C G, Paulson R, Wong T, Bauer K A, Schwartz B A, Miletich J P, Bounameaux H, Glynn R J. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348 (15): 1425-34.

Sharrock N E, Go G, Sculco T P, Salvati E A, Westrich G H, Harpel P C. Dose response of intravenous heparin on markers of thrombosis during primary total hip replacement. Anesthesiology 1999; 90 (4): 981-7.

Sudo A, Wada H, Nobori T, Yamada N, Ito M, Niimi R, Hasegawa M, Suzuki K, Uchida A. Cut-off values of D-dimer and soluble fibrin for prediction of deep ven thrombosis after orthopaedic surgery. Int J Hematol 2009; 89 (5): 572-6.

Sugano N, Miki H, Nakamura N, Aihara M, Yamamoto K, Ohzono K. Clinical efficacy of mechanical thromboprophylaxis without anticoagulant drugs for elective hip surgery in an Asian population. J Arthroplasty 2009; 24 (8): 1254-7.

The first edition guidelines for prevention of venous thromboembolism. Tokyo [in Japanese]: Medical Front International Limited; 2004.